Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma

A 4-week, Open-label, Randomized, Multi-centre, Parallel-group Study Evaluating the Safety and Efficacy of 4 Actuations Symbicort® (Budesonide/Formoterol) HFA pMDI 40/2.25 μg Twice Daily, With and Without Spacer, in Children (6-11 Years) With Asthma

The purpose of the study is to compare Symbicort pMDI with and without spacer in terms of steroid potency, improvement of lung function and asthma symptoms in children with asthma (6-11 years).

Inclusion Criteria:

• children 6-11 years, diagnosed asthma treated
• 6 months, PEF
• 50% of predicted normal value pre-bronchodilator

Exclusion Criteria:

• current systemic glucocorticosteroids usage
• current respiratory infection
• any significant disease or disorder as judged by investigator